Home Title Index Topic Index Sources Directory News Releases Sources Calendar RSS Sources Select News RSS Feed

Anavex files Phase I regulatory submission for ANAVEX 2-73 in Alzheimer's disease
Sources News Release

http://www.sources.com/Releases/NR1117.htm

Publisher:  Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biot
Date Written:  11/01/2011
Year Published:  2011  
Resource Type:  Article

Anavex Life Sciences Corp. has filed regulatory submission for ANAVEX 2-73 with the German Health Authority, BfArM, and the local Ethics Committee of Saxony to begin clinical studies for ANAVEX 2-73, its lead compound for the treatment of Alzheimer

Abstract:  Meets major clinical development milestone for lead compound
December 21, 2010
Hoboken, NJ – December 21, 2010 - Anavex Life Sciences Corp. (“Anavex”, AVXL:OB) announced today that it has filed the regulatory submission for ANAVEX 2-73 with the German Health Authority, BfArM, and the local Ethics Committee of Saxony to begin clinical studies for ANAVEX 2-73, its lead compound for the treatment of Alzheimer's disease.

"This regulatory filing marks an important milestone in the clinical devel...
To read the full release go to http://www.sources.com/Releases/NR1117.htm

Topics


Sources-journalists use the sources website to find you


AlterLinks
c/o Sources


© 2018. The information provided is copyright and may not be reproduced in any form or by any means (whether electronic, mechanical or photographic), or stored in an electronic retrieval system, without written permission of the publisher. The content may not be resold, republished, or redistributed. Indexing and search applications by Ulli Diemer and Chris DeFreitas.